Impact of statins and ACE inhibitors on mortality after COPD exacerbations

[1]  V. Debari,et al.  Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study , 2008, International journal of clinical practice.

[2]  M. Joo,et al.  Patterns of Healthcare Utilization by COPD Severity: A Pilot Study , 2008, Lung.

[3]  Samy Suissa,et al.  Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.

[4]  D. Fedson.  Statin protection against influenza and COPD mortality. , 2007, Chest.

[5]  P. Arbogast,et al.  Statins and influenza/COPD mortality. , 2007, Chest.

[6]  Toshinori Yoshida,et al.  Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. , 2007, Physiological reviews.

[7]  B. Skipper,et al.  Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. , 2007, Chest.

[8]  T. Omland,et al.  Statin use is associated with reduced mortality in COPD , 2006, European Respiratory Journal.

[9]  Mph Min J. Joo MD,et al.  Geographic Variation in Chronic Obstructive Pulmonary Disease Exacerbation Rates , 2007, Journal of General Internal Medicine.

[10]  Marsha A Raebel,et al.  Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures , 2006, The Annals of pharmacotherapy.

[11]  M. Etminan,et al.  Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. , 2006, Journal of the American College of Cardiology.

[12]  K. Weiss,et al.  Spirometry use in clinical practice following diagnosis of COPD. , 2006, Chest.

[13]  S. Kritchevsky,et al.  Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. , 2005, American journal of respiratory and critical care medicine.

[14]  B Graeme Fincke,et al.  Potentially Inappropriate Prescribing in Elderly Veterans: Are We Using the Wrong Drug, Wrong Dose, or Wrong Duration? , 2005, Journal of the American Geriatrics Society.

[15]  Sean D Sullivan,et al.  Methods to assess intended effects of drug treatment in observational studies are reviewed. , 2004, Journal of clinical epidemiology.

[16]  J. Piette,et al.  Problems due to medication costs among VA and non-VA patients with chronic illnesses. , 2004, The American journal of managed care.

[17]  Donald R. Miller,et al.  The Health Status of Elderly Veteran Enrollees in the Veterans Health Administration , 2004, Journal of the American Geriatrics Society.

[18]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[19]  D. Honeybourne,et al.  Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD , 2004, European Respiratory Journal.

[20]  D. Makuc,et al.  Health, United States, 2003; with chartbook on trends in the health of Americans , 2003 .

[21]  Charles Maynard,et al.  A primer and comparative review of major US mortality databases. , 2002, Annals of epidemiology.

[22]  M Maclure,et al.  Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. , 2001, American journal of epidemiology.

[23]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. , 2001, Respiratory care.

[24]  J. Cramer,et al.  A systematic review of the associations between dose regimens and medication compliance. , 2001, Clinical therapeutics.

[25]  K. Chung,et al.  Cytokines in chronic obstructive pulmonary disease , 2001, European Respiratory Journal.

[26]  S. Grundy,et al.  Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.

[27]  S. Skerrett,et al.  Anti-inflammatory treatment of acute and chronic pneumonia. , 2001, Seminars in respiratory infections.

[28]  B. Grant,et al.  Airway inflammation and etiology of acute exacerbations of chronic bronchitis. , 2000, Chest.

[29]  K. Morgan,et al.  A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. , 2000, Chest.

[30]  J. Kellum,et al.  UNINTENDED IMMUNOMODULATION: PART II. EFFECTS OF PHARMACOLOGICAL AGENTS ON CYTOKINE ACTIVITY , 2000, Shock.

[31]  S. Frøland,et al.  Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. , 1999, Journal of the American College of Cardiology.

[32]  T. Strandberg,et al.  Effect of statins on C-reactive protein in patients with coronary artery disease , 1999, The Lancet.

[33]  R. Stockley.  Lung infections. 1. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection. , 1998, Thorax.

[34]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.

[35]  M. Fine,et al.  Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Pneumonia Patient Outcomes Research Team (PORT) Investigators. , 1995, Medical care.

[36]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[37]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[38]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .